Catalent, NewMarket in Animal Product Pact

Catalent Pharma Solutions and NewMarket Pharmaceuticals have entered into an agreement to jointly formulate and develop a portfolio of products for treating production and companion animals using Catalent’s Zydis fast-dissolve technology and NewMarket’s DSI platform (Direct Systemic Introduction, patent pending).

NewMarket is currently developing five drugs that will combine Catalent’s Zydis fast-dissolve and its DSI technologies, initially including NSAIDs, beta agonists, proton pump inhibitors, and behavior modifiers across a variety of species including horses, dogs, and cattle, with plans to expand the range in other classes. These new animal health products are expected to provide significant advantages over existing formulations currently used.

Mark Ridall, chief executive officer of NewMarket Pharmaceuticals, said, “These easy-to-use formulations could revolutionize the way we treat animals by providing a simple, efficient, accurate method of treatment without the use of needles.”
 
“This partnership with NewMarket Pharmaceuticals demonstrates not only our commitment to provide more products and better treatments to our customers, but also signifies the versatile benefits that our Zydis fast-dissolve technology continues to deliver,” said Paul Jenkins, global vice president of Catalent’s ODT business.